Safety of Tocilizumab on Rheumatoid Arthritis in Patients with Interstitial Lung Disease.
Naotatsu OtsujiKumiya SugiyamaTakayoshi OwadaHajime ArifukuKenya KoyamaHirokuni HirataYasutsugu FukushimaPublished in: Open access rheumatology : research and reviews (2024)
RA activity and ILD activity were found to be related at 6 months of treatment. Tocilizumab does not seem to affect the mechanism of ILD progression, as most patients showed improvement in both MMP-3 and KL-6 with tocilizumab within 6 months, when this drug would be expected to affect the lungs directly. However, respiratory infection exacerbated ILD from 1 year after the start of treatment. As immunosuppressive drugs, including tocilizumab, have a risk of respiratory infection, it is important to identify early signs of infection.
Keyphrases
- interstitial lung disease
- rheumatoid arthritis
- systemic sclerosis
- disease activity
- ankylosing spondylitis
- idiopathic pulmonary fibrosis
- end stage renal disease
- rheumatoid arthritis patients
- chronic kidney disease
- juvenile idiopathic arthritis
- ejection fraction
- prognostic factors
- drug induced
- emergency department
- systemic lupus erythematosus
- patient reported outcomes
- cell migration
- respiratory tract
- patient reported